LLY

991.3

+2.58%↑

JNJ

225.29

+2.16%↑

ABBV

208.22

+2.7%↑

UNH

394.25

+3.26%↑

AZN

185.01

+1.58%↑

LLY

991.3

+2.58%↑

JNJ

225.29

+2.16%↑

ABBV

208.22

+2.7%↑

UNH

394.25

+3.26%↑

AZN

185.01

+1.58%↑

LLY

991.3

+2.58%↑

JNJ

225.29

+2.16%↑

ABBV

208.22

+2.7%↑

UNH

394.25

+3.26%↑

AZN

185.01

+1.58%↑

LLY

991.3

+2.58%↑

JNJ

225.29

+2.16%↑

ABBV

208.22

+2.7%↑

UNH

394.25

+3.26%↑

AZN

185.01

+1.58%↑

LLY

991.3

+2.58%↑

JNJ

225.29

+2.16%↑

ABBV

208.22

+2.7%↑

UNH

394.25

+3.26%↑

AZN

185.01

+1.58%↑

Home・Stock List・Denali Therapeutics Inc

Denali Therapeutics Inc

Open

SectorHealthcare

19.3 -1.88

Buy Sell

Overview

Share price change

24h

Current

Min

19.07

Max

19.89

Key metrics
By Trading Economics
Income	-1.6M -129M
Employees	503
EBITDA	8.9M -125M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+83.48% upside

Dividends
By Dow Jones
Next Earnings	7 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-295M 3B
Previous open	21.18
Previous close	19.3

News Sentiment

By Acuity

47%

53%

161 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

13.355 / 16.44 Support & Resistance

Denali Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

11 May 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 May 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 May 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 May 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 May 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 May 2026, 22:32 UTC

Earnings

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 May 2026, 22:02 UTC

Market Talk

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 May 2026, 21:49 UTC

Earnings

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 May 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 May 2026, 21:32 UTC

Acquisitions, Mergers, Takeovers

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 May 2026, 21:31 UTC

Acquisitions, Mergers, Takeovers

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 May 2026, 21:23 UTC

Acquisitions, Mergers, Takeovers

CSG Systems Sale to NEC Gets CFIUS Clearance

11 May 2026, 21:12 UTC

Earnings

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 May 2026, 21:12 UTC

Earnings

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 May 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 May 2026, 20:44 UTC

Earnings

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 May 2026, 20:43 UTC

Earnings

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 May 2026, 20:32 UTC

Earnings

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 May 2026, 20:32 UTC

Earnings

CleanSpark 2Q Rev $136.4M >CLSK

11 May 2026, 20:30 UTC

Earnings

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 May 2026, 20:30 UTC

Earnings

Steris 4Q Cont Ops EPS $2.24 >STE

11 May 2026, 20:30 UTC

Earnings

Steris 4Q Rev $1.6B >STE

11 May 2026, 20:30 UTC

Earnings

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 May 2026, 20:30 UTC

Earnings

Steris 4Q Adj EPS $2.83 >STE

11 May 2026, 20:22 UTC

Hot Stocks

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 May 2026, 19:37 UTC

Earnings

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 May 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Comparison

Price change

Denali Therapeutics Inc Forecast

Price Target

By TipRanks

83.48% upside

12 Months Forecast

Average 36.09 USD 83.48%

High 42 USD

Low 23 USD

Based on 14 Wall Street analysts offering 12 month price targets forDenali Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

Buy

Hold

Sell

Based on 14 analysts giving stock ratings to Denali Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

13.355 / 16.44Support & Resistance

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentiment

By Acuity

161 / 346 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.